- Home
- VITL vs AUTL Comparison
VITL vs AUTL Comparison
Compare VITL & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VITL | AUTL |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.9M | 596.2M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | VITL | AUTL |
|---|---|---|
| Price | $9.74 | $1.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $32.00 | $8.50 |
| AVG Volume (30 Days) | 1.2M | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $759,444,000.00 | $10,120,000.00 |
| Revenue This Year | $19.72 | $80.32 |
| Revenue Next Year | $17.02 | $53.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.26 | ★ 496.00 |
| 52 Week Low | $7.95 | $1.18 |
| 52 Week High | $49.04 | $2.58 |
Technical Indicators
Market Signals| Indicator | VITL | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 33.60 | 41.17 |
| Support Level | $7.95 | $1.37 |
| Resistance Level | $10.60 | $2.07 |
| Average True Range (ATR) | 0.47 | 0.10 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 2.39 | 1.79 |
Price Performance
Historical ComparisonAbout VITL Vital Farms Inc.
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.